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Abstract
Hypertrophic cardiomyopathy (HCM) is characterized by substantial genetic and phenotypic heterogeneity, leading
to considerable diversity in clinical course including the most common cause of sudden death in young people
and a determinant of heart failure symptoms in patients of any age. Traditionally, two-dimensional
echocardiography has been the most reliable method for establishing a clinical diagnosis of HCM. However,
cardiovascular magnetic resonance (CMR), with its high spatial resolution and tomographic imaging capability, has
emerged as a technique particularly well suited to characterize the diverse phenotypic expression of this complex
disease. For example, CMR is often superior to echocardiography for HCM diagnosis, by identifying areas of
segmental hypertrophy (ie., anterolateral wall or apex) not reliably visualized by echocardiography (or
underestimated in terms of extent). High-risk HCM patient subgroups identified with CMR include those with thin-
walled scarred LV apical aneurysms (which prior to CMR imaging in HCM remained largely undetected), end-stage
systolic dysfunction, and massive LV hypertrophy. CMR observations also suggest that the cardiomyopathic process
in HCM is more diffuse than previously regarded, extending beyond the LV myocardium to include thickening of
the right ventricular wall as well as substantial morphologic diversity with regard to papillary muscles and mitral
valve. These findings have implications for management strategies in patients undergoing invasive septal reduction
therapy. Among HCM family members, CMR has identified unique phenotypic markers of affected genetic status in
the absence of LV hypertrophy including: myocardial crypts, elongated mitral valve leaflets and late gadolinium
enhancement.
The unique capability of contrast-enhanced CMR with late gadolinium enhancement to identify myocardial fibrosis
has raised the expectation that this may represent a novel marker, which may enhance risk stratification. At this
time, late gadolinium enhancement appears to be an important determinant of adverse LV remodeling associated
with systolic dysfunction. However, the predictive significance of LGE for sudden death is incompletely resolved
and ultimately future large prospective studies may provide greater insights into this issue. These observations
underscore an important role for CMR in the contemporary assessment of patients with HCM, providing important
information impacting diagnosis and clinical management strategies.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most com-
mon genetic cardiomyopathy (prevalence of 1:500 in the
general population) caused by mutations in genes
encoding proteins of the cardiac sarcomere [1-5]. A
clinical diagnosis of HCM is confirmed when unex-
plained increased LV wall thickness is imaged (range
13-60 mm with average 22 mm) in the presence of a
nondilated LV chamber [1,3,6]. HCM is a global disease
affecting many races and equally by gender [7,8].
Despite a diverse pattern of phenotypic expression and
clinical course, HCM is compatible with normal life
expectancy in the vast majority of patients [9-11]. How-
ever, a small but important subset of HCM patients
remain at increased risk of adverse disease complica-
t i o n ss u c ha ss u d d e nd e a t h ,p r o g r e s s i v eh e a r tf a i l u r e
symptoms or stroke [1,12-15].
Genetics. HCM is caused by vast genetic heterogeneity
with > 1,400 mutations in 13 or more genes encoding
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any medium, provided the original work is properly cited.contractile proteins of the cardiac sarcomere (or in sar-
comere-associated proteins) with cardiac b-myosin
heavy chain (MYH7) and cardiac myosin binding pro-
tein C (MYBPC3)(Figure 1) the two most common sar-
comere mutant genes, each accounting for the majority
of HCM [5,16-18]. Mutations responsible for HCM are
transmitted in an autosomal dominant manner in which
each offspring of an affecting family member has a 50%
chance of inheriting the mutation. Nearly all patients
who inherent a disease-causing mutation will demon-
strate evidence of the disease with increased wall thick-
ness by early adulthood. However, select mutations can
demonstrate substantial variability in age-related pene-
trance, resulting in delayed expression of the phenotype
into the third decade of life, or even beyond to mid-life
[19].
Currently, clinic genetic testing can identify a sarco-
mere protein mutation in 50-60% of patients with a phe-
notype of HCM [17,20,21]. Therefore, the genetic basis
of a substantial number of patients with phenotypic evi-
dence of HCM remains uncertain [20]. However, in
those HCM index patients in whom a mutation is iden-
tified, genetic testing can then provide the opportunity
to identify relatives at-risk of developing disease
[17,20-22]. For relatives identified as having a mutation
but without left ventricular hypertrophy (ie., genotype
positive/phenotype negative) it is likely that this patient
will develop phenotypic evidence of disease at some
point in there clinical course, prompting recommenda-
tions for continued imaging surveillance [23]. For those
family members who do not carry the mutation there is
no future risk of developing HCM and therefore no
further testing is necessary [17,21].
Genetic testing can also differentiate a number of
uncommon systemic metabolic diseases, which can
manifest a pattern of LV hypertrophy nearly identical to
that of sarcomeric HCM but which have different treat-
ment strategies. These diseases are due to mutations in
encoding the g2 regulatory subunit of adenosine mono-
phosphateactivated protein kinase (PRKAG2), lysosome
associated membrane protein (LAMP2) and the recessive
disorder Fabry disease caused by mutations in the gene
a-galactosidase (GLA) [17,21,24].
Currently, identifying HCM patients at risk for adverse
disease-related events including sudden death cannot be
predicted based on specific mutations [16,17,20,21,25].
As a result, management decisions such as ICD therapy
for primary prevention cannot be made solely based on
results derived from genetic testing [21,26]. Further-
more, the observation that disease expression among
first-degree family members with HCM can be dramati-
cally different as well as the fact that specific HCM phe-
notypes (ie., apical HCM, apical aneurysms, end-stage
HCM, etc.) have diverse mutations associated with
Figure 1 Cardiac sarcomere showing the location of known disease-causing genes for HCM. Adapted from Wheeler et al.[20] Not
shown are genes previously linked to HCM, but with lesser degrees of evidence for disease causing: titin, vinculin, muscle LIM protein,
telethonin, cardiac ankyrin repeat protein, calreticulin 3, calsequestrin 2, phospholamban, ryanodine receptor 2.
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mutation and phenotype [27]. The explanation for these
o b s e r v a t i o n sm a yb ed u et oan u m b e ro fl e s sw e l l -
understood factors, such as how modifier genes and
environment also contribute to HCM disease expression
[4].
Cardiovascular magnetic resonance (CMR)
Cardiovascular magnetic resonance (CMR) has recently
emerged as an important imaging technique by offering
a number of unique strengths which make it particularly
well suited to provide detailed characterization of the
HCM phenotype and therefore an important aid for
diagnosis and potentially prognosis [28-34]. CMR can
provide 3-dimensional tomographic imaging with high
spatial and temporal resolution images of the heart, in
any plane and without ionizing radiation (Figure 2) [30].
Contemporary functional cine CMR imaging sequences
(ie., steady-state free precession) allow clear delineation
of the endocardial and epicardial borders by producing
sharp contrast between the interface of darkened myo-
cardium and bright blood pool, which permit for precise
wall thickness measurements in any location of the LV
myocardium [34]. Furthermore, CMR provides truly
tomographic imaging by acquiring a stack of short-axis
images (with no interslice gap) with full ventricular cov-
erage and therefore the opportunity to inspect the LV
myocardium for limited, focal hypertrophy [29,35]. CMR
images are not encumbered by the same limitations
inherent in echocardiographic imaging, such as poor
image quality related to thoracic or pulmonary parench-
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Figure 2 CMR end-diastolic images demonstrating diverse patterns of LVH in HCM. (A) involving ventricular septum (VS), but sparing the
LV free wall (FW); (B) hypertrophy of the basal anterior free wall and a portion of the contiguous anterior septum, representing the most
common area of LV wall thickening in HCM; (C) massive hypertrophy (wall thickness, 33 mm) limited to basal posterior ventricular septum
(asterisk); (D) focal area sharply confined to basal anterior septum (arrows); (E) localized to LV apex (asterisks); (F) segmental LV hypertrophy of
the basal anterior septum and anterolateral wall (asterisks), separated by regions of normal LV thickness (arrows). Adapted with permission, from
Maron MS et al.[29] FW = free wall; LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle; VS = ventricular septum.
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be identified with contrast-enhanced CMR sequences
after the intravenous injection of gadolinium images,
which may select patients at i n c r e a s e dr i s ko fa d v e r s e
disease consequences [36-39].
CMR for Diagnosis
Traditionally, two-dimensional echocardiography has
been the primary imaging modality used for a clinical
diagnosis of HCM by demonstrating an otherwise unex-
plained increase in LV wall thickness (avg., 21-22 mm)
in the presence of a nondilated LV cavity [1,40,41].
However, over the last decade, several important obser-
vations have emerged related to the role of CMR in the
diagnosis of HCM. First, when echocardiographic
images are technically suboptimal and nondiagnostic,
CMR has the distinct advantage of defining LV wall
thickness measurements with high-resolution imaging
[33,41]. Second, CMR has proved advantageous in iden-
tifying the presence and/or magnitude of LV hypertro-
phy, particularly when regions of increased wall
thickness are completely (or predominantly) limited to
only focal areas of the LV wall such as the anterior free
wall, posterior septum and apex [29,35,42-45]. In one
recent study, an important subset of patients with HCM
were ultimately diagnosed with this disease only after
LV hypertrophy was recognized in the anterolateral wall
by CMR [35], suggesting this may be the most common
area of the LV wall in which hypertrophy may be missed
by echocardiography (Figure 3a and 3b). This
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Figure 3 CMR can identify segmental LV hypertrophy that may not be reliably visualized by two-dimensional echocardiography.( A)
normal 2-D echocardiogram in a patient with a family history of HCM; (B) this same patient then underwent CMR, which reveals an area of
segmental hypertrophy in the anterolateral LV wall (asterisk) consistent with a diagnosis of HCM. Reproduced with permission of American Heart
Association; from Rickers C et al.;[35] (C) two-dimensional echocardiographic end-diastolic basal short-axis view demonstrates a maximal LV wall
thickness of 18 mm in the anterolateral free wall consistent with the diagnosis of HCM; (D) in the same patient, an end-diastolic short-axis CMR
at the same level of LV shows a focal area of massive LV hypertrophy (35 mm) in the same region of the LV wall reported to be 18 mm by
echocardiography. The finding of massive hypertrophy by CMR, characterized this patient as high risk, and prompted recommendation for ICD
therapy for primary prevention of sudden death. Reproduced with permission, from Maron MS et al.;[42](E) echocardiography was considered
non-diagnostic; (F) in the same patient, CMR clearly demonstrates segmental hypertrophy confined to the LV apex, consistent with a diagnosis
of apical HCM. Reproduced with permission, from Moon et al.[43] LV = left ventricle; RV = right ventricle; VS = ventricular septum.
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ferentiating the lateral epicardial border of the LV myo-
cardium from the adjacent thoracic parenchyma in the
short-axis orientation due to loss of spatial resolution in
that portion of the imaging sector by echocardiography.
For similar reasons, defining the epicardial border of the
posterior septum in the area of insertion of the RV free
wall can also be difficult with echocardiography [29].
Lastly, in some patients, thoracic and pulmonary par-
enchyma may limit the ability of echocardiocardiography
to accurately define the endo or epicardial border of the
apex, while CMR is not limited by such constraints (Fig-
ure 3c and 3d) [43-45]. These observations also support
the wider use of CMR in screening family members [23].
Phenotype Characterization
Pattern and distribution of LV hypertrophy
The most common location for increased LV wall thick-
ness in HCM patients is the confluence of the basal
anterior septum with the contiguous anterior free wall
(ie., one o’clock position in the LV short-axis image; Fig-
ure 2b) [29]. Hypertrophy involving both of these seg-
ments is present in close to 70% of HCM patients and
therefore this region of the LV constitutes the most fre-
quent location for increased wall thickness in this dis-
ease. Due to the aforementioned limitations in
accurately identifying the borders of these wall segments
with lower spatial resolution echocardiography, this
CMR observation in HCM differs from that of the
impression of echocardiography in which the predomi-
nant area of hypertrophy was the basal anterior septum
(ie., 12 o’clock position) [40]. In a population of HCM
patients, the next most common region for increased
wall thickness is the posterior septum at the mid-LV
level (Figure 2c) [29].
The majority of HCM patients have diffuse hypertro-
phy involving more than 50% or greater of the LV myo-
cardium (Figure 2a). Notably, a substantial minority of
HCM patients have particularly focal or regional areas
of increased wall thickness involving only one or two
LV segments most commonly involving the basal ante-
rior septum (Figure 2d) but also the anterolateral free
wall, posterior septum and apex (Figure 2e) [29]. In
addition, LV mass is normal in a substantial portion of
HCM patients with limited, focal hypertrophy [46].
These CMR-based observations emphasize an important
principle that even very limited hypertrophy (with nor-
mal LV mass), can be consistent with a clinical diagnosis
of HCM [29,46].
Right ventricle
Historically, a number of important limitations of 2-D
echocardigraphy have made it difficult to accurately
characterize the presence of RV morphologic abnormal-
ities in patients with HCM. However, CMR has
demonstrated a number of abnormalities including
increased maximal RV wall thickness (ie., ≥ 8 mm) in
over one-third of HCM patients and in a substantial
proportion of patients RV wall mass is also increased
[47,48]. Areas of increased RV wall thickness are most
commonly seen near the junction of the insertion of the
RV wall into either the anterior or posterior septum
(Figure 4a), although involvement of the entire RV does
occur [47]. The totalities of these CMR-based observa-
tions expand on previous echocardiographic observa-
tions by demonstrating that the spectrum of phenotypic
expression in HCM also includes morphologic abnorm-
alities of the RV, although the prognostic significance of
RV hypertrophy in HCM remains uncertain.
In addition to RV hypertrophy, CMR can also identify
prominent RV muscle structures, such as the crista
supraventricularis (Figure 5a). On the basal short-axis
images this RV muscle structure is frequently situate
adjacent to the ventricular septum and therefore incor-
rectly included in the measurement of maximal LV wall
thickness (potentially resulting in an overestimation of
wall thickness measurements; Figure 5b) [47]. However,
with close visual inspection of the contiguous stack of
short-axis cine CMR images, the crista muscle structure
can be seen on certain short-axis slices to separate from
the septum in diastole exposing the epicardial border of
the ventricular septum allowing one to more easily
delineate the epicardial border of ventricular septum
(Figure 5b). In addition, HCM patients can develop sub-
pulmonic RV obstruction due to substantial narrowing
of the RV outflow tract from excessive hypertrophy of
the RV free wall and ventricular septum. In those HCM
patients considered for surgical relief of RV outflow
tract obstruction, CMR can characterize the precise
location and extent of hypertrophy in this region provid-
ing the surgeon information to help guide pre-operative
surgical management.
LV apical aneurysms
HCM patients with thin-walled apical aneurysms asso-
ciated with mid-ventricular hypertrophy represent an
important subgroup of HCM patients who had been
under diagnosed prior to the application of CMR to
HCM (Figure 4b) [33,49,50]. This is largely due to the
fact that small to moderate sized apical aneurysms may
not be reliably detected with echocardiography for the
same reasons that apical hypertrophy can also be missed
[43,44,50,51]. Contrast-enhanced CMR has demon-
strated that apical aneurysms are composed predomi-
nantly of fibrosis [49,50]. However, LGE often extends
from the rim of the aneurysm into the septum and free
wall with the junction of these areas representing a
nidus for the generation of ventricular tachyarrhythmias
[52]. Indeed, these morphologic changes related to the
apex are likely what places these HCM patients at
Maron Journal of Cardiovascular Magnetic Resonance 2012, 14:13
http://www.jcmr-online.com/content/14/1/13
Page 5 of 21increased risk of arrhythmic sudden death and stroke
and thus represent a high-risk subgroup. Therefore, the
diagnosis of patients with apical aneurysm directly
impacts management recommendations for these
patients, including consideration for ICD therapy and/or
coumadin for stroke prophylaxis [49-51].
Mitral Valve
CMR has demonstrated that mitral valve abnormalities
represent a primary phenotypic expression of this com-
plex disease, suggesting that pathophysiologic pathways
other than those related to the primary sarcomere dis-
ease-causing mutation may be important in contributing
to aspects of HCM disease expression independent of
LV hypertrophy [53]. Mitral valve leaflets are increased
in length in many HCM patients, including over one-
third of patients with substantially elongated anterior (≥
30 mm)(Figure 4d) or posterior mitral leaflet lengths (≥
17 mm) [53]. Leaflet lengths are elongated independent
of a number of important HCM disease variables includ-
ing: age, LV thickness or the presence of outflow tract
obstruction. Therefore, these morphologic valvular
abnormalities likely represent a primary phenotypic
expression of this disease.
Elongated mitral valve leaflets also contribute substan-
tially to the mechanism responsible for subaortic gradi-
ents, particularly in those select HCM patients in whom
Figure 4 CMR end-diastolic images demonstrating diversity of the phenotypic expression within HCM. (A) increased wall thickness in the
superior segment (thin arrow) and extreme hypertrophy of the inferior segment (thick arrow) of the RV wall; Reproduced with permission, from
Maron MS et al.[29](B) medium-sized LV apical aneurysm (arrowheads) and maximal LV wall thickening at mid-ventricular level with muscular
apposition of septum and LV free wall producing distinct proximal (P) and distal chambers; Reproduced with permission, from Maron MS et al.
[50](C) anomalous insertion of papillary muscle (thin arrows) directly into the anterior leaflet of the mitral valve (thick arrow) (in the absence of
chordae tendinae) producing obstruction to blood flow from the apposition of the papillary muscle and basal ventricular septum (asterisk); (D)
extraordinarily long anterior mitral valve leaflet measuring 33 mm; PML is of normal length (although not well visualized in this frame);
Reproduced with permission, from Maron MS et al.[53](E) multiple accessory papillary muscles, 4 in number (arrows); Reproduced with
permission from Harrigan C et al.[54](F) 7-year-old asymptomatic genotype positive/phenotype negative HCM girl with 3 deep myocardial crypts
in the basal (posterior) inferior LV free wall. Ao = aorta; RV = right ventricle; LA = left atrium; LV = left ventricle; VS = ventricular septum
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dimension of the outflow tract at end-systole [53].
Therefore, substantially elongated mitral valve leaflets
are an important determinant of LV outflow tract
obstruction in some HCM patients, with implications
for management strategies in this disease (See surgical
myectomy section below).
Papillary Muscles
CMR has also expanded our appreciation of other mor-
phologic abnormalities in patients with HCM in addi-
tion to those of the LV and RV wall, including the fact
that abnormalities in papillary muscle morphology are
common in HCM disease expression [54,55]. HCM
patients frequently have an increase in the number of
papillary muscles, including close to half of patients
with 3 or 4 papillary muscles (Figure 4e) [54,55]. Hyper-
trophy of the papillary muscles is also common, includ-
ing greater than half of HCM patients demonstrating a
2-fold greater papillary muscle mass compared with
than controls. Furthermore, there appears to be a sub-
group of HCM patients with normal LV mass (but with
localized increase in wall thickness), who nevertheless
showed substantially hypertrophied papillary muscles
with increased mass (20% of patients) [54]. In such
patients, the cardiomyopathic process either dispropor-
tional involved papillary muscles (compared to the LV
wall), or preferentially affected the papillary muscles.
Therefore, similar to the RV, LV papillary muscles
appear be part of the cardiomyopathic process in HCM.
Genotype Positive/Phenotype Negative HCM Patients
The recent penetration of commercial genetic testing
has resulted in the increased recognition of family mem-
ber of HCM patients who carry a disease-causing sarco-
mere mutation but without LV hypertrophy (genotype
positive/phenotype negative [G+/P-]) [17,21,23]. A vari-
ety of potential morphologic abnormalities may be pre-
sent in G+/P- HCM patients and identified by CMR.
Figure 5 Right ventricular crista supraventricularis in HCM. When determining. where to measure the maximal LV wall thickness, it is
important to be aware that HCM patients often have prominent and hypertrophied right ventricular muscular structures, the most common of
which is the crista supraventricularis. In some HCM patients, the crista supraventricularis is not only significantly hypertrophied (panel A, outlined
in red) but not uncommonly inserts from its origin in the RV cavity to directly adjacent to the ventricular septum. As a result, this RV muscle
structure may be inappropriately included in the measurement of septal thickness—resulting in an overestimation of the maximal LV wall
thickness; Reproduced with permission, from Maron MS et al.[47]. In order to avoid including the crista supraventricularis as part of the septum,
close inspection of the CMR short-axis cine images can help clarify this issue; (B) in a different HCM patient than panel A, the crista
supraventicularis muscle is noted to move away from the septum toward the RV cavity with a small area of blood pool noted between the
crista and septum (arrow), allowing for a more accurate delineation of the epicardial border of the septum (asterisk).
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myocardial crypts (ie., narrow, deep blood-filled invagi-
nations within LV myocardium) localized predominantly
to the basal posterior septum and LV free wall (Figure
4f) [56,57], although additional studies are needed to
determine precisely how common crypts are in G+P-
HCM patients compared to individuals without cardio-
vascular disease. In addition, elongated mitral valve leaf-
lets [53], and LGE [58-60] may also be markers for gene
positive status in HCM family members in the absence
of LV hypertrophy. These CMR-based findings represent
important clinical and morphologic abnormalities, which
expand our current appreciation with respect to disease
expression of G+ P- patients and provide evidence that
even in the absence of hypertrophy hearts may be mor-
phologically abnormal in this novel and emerging sub-
group of HCM patients.
Furthermore, these observations support an expanded
role for CMR in earlier diagnosis of relatives within
HCM families [23,58]. For example, the identification of
one of these morphologic abnormalities by CMR in a
relative of an HCM patient in whom genetic testing can-
not be performed due to cost or other considerations
(or the mutation remains undefined even after testing),
should prompt close surveillance with imaging studies
to detect development of the phenotype. Also, in
patients who can undergo genetic testing, identification
of one of these morphologic abnormalities underscores
the importance of pursuing genotyping to achieve defi-
nitive HCM diagnosis [17,21,23].
Role for CMR in Differential Diagnosis of LV hypertrophy
Metabolic and Infiltrative Cardiomyopathies
Although sarcomeric HCM accounts for the majority of
unexplained left ventricular hypertrophy seen in adults,
a number of other non-sarcomeric diseases can produce
increased wall thickness of the myocardium as part of
their phenotypic expression. Infiltrative cardiomyopa-
thies such as cardiac amyloidosis, glyocogen/lysosomal
storage diseases including Fabry’s, Danons, and AMP
kinase are considered to be the most common non-sar-
comeric diseases in which cardiac phenotypic expression
can mimic that of HCM (ie., “phenocopies”)[ 6 1 ] .
Fabry’s disease is an X-linked storage disease in which
mutations in the a-galactosidase A gene lead to cellular
accumulation of glycoshpingolipids in multiple organs,
including the heart. Cardiac manifestations typically
include left ventricular hypertrophy, valvular disease,
atrial/ventricular arrhythmias and chest pain due to
microvascular ischemia [61]. Although cardiac manifes-
tations can occur early in life, they are generally not
detected until the third or fourth decade but remain a
major cause of death in patients with Fabry’s[ 6 1 ] .
Danon disease is another X-linked lysosomal storage
disease which can also result in systemic manifestations
with associated cardiomyopathy. Clinical suspicion of
Danon disease can be raised when young patients pre-
sent with LV hypertrophy and a 12-lead electrocardio-
gram with pre-excitation pattern (ie., Wolf-Parkinson-
White syndrome) [62]. Rapid clinical deterioration has
been observed in patients with Danon disease (often
occurring < 25 years of age), leading commonly to heart
failure death and even sudden cardiac death [62].
Although these diseases most often have non-cardiac
signs and symptoms, in rare instances disease expression
can be confined to only the heart [62].
An accurate diagnosis early in clinical presentation is
critical, as treatment strategies and prognosis may differ
for these diseases compared to HCM [24]. CMR may
raise suspicion that a patient does not have HCM, when
diagnosis remains uncertain after traditional imaging
with two-dimensional echocardiography. For example,
the demonstration with cine CMR of nearly identical
increased wall thickness measurements in both the sep-
tum and LV free wall (ie., “concentric”) combined with
global subendocardial LGE on contrast-enhanced images
is highly specific for cardiac amyloidosis [63]. A similar
pattern of concentric wall thickening with LGE confined
to the basal inferolateral wall has been frequently
reported in Fabry disease [64]. Although CMR findings
may suggest that the etiology of LV hypertrophy in an
individual patient may be due to a metabolic/infiltrative
cardiomyopathy rather than sarcomeric HCM, no pat-
tern of LV wall thickening or LGE is pathogeumonic
and therefore confirmatory diagnosis of these diseases
ultimately requires the identification of a disease-causing
mutation with genetic testing or typical histopathology
on cardiac biopsy [17].
LV noncompaction
Furthermore, due to its super spatial resolution in ima-
ging the distal LV myocardium, CMR may also help
clarify (and even alter) diagnosis by demonstrating the
presence of prominent trabeculations (ie., sinusoids)
consistent with a diagnosis of LV noncompaction in
patients initially diagnosed with apical HCM [65]. In
this regard, the LV trabeculations associated with LV
noncompaction may appear as apical hypertrophy when
imaged with lower spatial resolution two-dimensional
echocardiography, potentially resulting in a misdiagnosis
of apical HCM in these patients. This also has important
implications for management strategies as a diagnosis of
LV noncompaction may have additional impact on
treatment strategies (ie., coumadin) [66].
Hypertensive Cardiomyopathy
Differentiating HCM from wall thickening due to hyper-
tension has historically represented a clinical challenge.
Invariably, exposure to long-standing systemic hyperten-
sion will result in nearly identical wall thickening in the
Maron Journal of Cardiovascular Magnetic Resonance 2012, 14:13
http://www.jcmr-online.com/content/14/1/13
Page 8 of 21septum and LV lateral wall (ie., concentric hypertrophy).
In addition, hypertensive cardiomyopathy is very rarely
associated with resting LV outflow tract obstruction due
to typical systolic anterior motion (SAM) with septal
contact. Likewise, LV wall thickening in HCM is almost
always asymmetric with resting outflow obstruction pre-
sent in over one-third of patients.
In addition, a subset of HCM patients demonstrate
non-contiguous patterns of LV wall thickening [29].
This morphologic pattern consists of hypertrophied seg-
ments separated by regions of non-hypertrophied myo-
cardium, creating abrupt changes in wall thickness in
adjacent portions of the wall and a “lumpy” hyper-
trophic pattern (Figure 2f). Such distribution of LV
hypertrophy is most consistent with a genetically deter-
mined cardiomyopathic process (such as HCM) rather
than those forms of hypertrophy secondary to pressure
overload (such as in systemic hypertension), and recog-
nition in selected patients could possibly contribute to
resolution of the differential diagnosis between HCM
and secondary hypertrophy from hypertension.
CMR can also be particularly helpful in detecting
changes in serial measurements of LV wall thickness
after treatment with antihypertensives, in which regres-
sion of hypertrophy would favor a diagnosis of hyper-
tensive cardiomyopathy. In addition, when the
distinction between these two disease entities still
remains otherwise ambiguous in an individual patient,
detection of HCM in family members who were pre-
viously undiagnosed or identification of a sarcomere
mutation with genetic testing would provide additional
evidence strongly favoring a clinical diagnosis of HCM.
Athlete’s Heart
In addition, it may also be difficult to differentiate HCM
from situations in which increased LV wall thickness
results as a secondary response to intense athletic train-
i n g .C M Rc a nh a v ear o l ei nd i f f e r e n t i a t i n gt h e s ec o n d i -
tions by identifying focal, limited hypertrophy not well
visualized by echocardiography [67]. CMR is well-suited
to accurately compare maximal LV wall thickness mea-
surements before and after a period of systematic
deconditioning. Patients in whom wall thickness
regresses greater than 2 mm supports a diagnosis of ath-
letes heart, while hypertrophy that remains unchanged
suggests HCM [67]. At present, it does not appear that
competitive athletes demonstrate LGE [68] and there-
fore the presence of LGE may also provide additional
information to confirm diagnosis of HCM.
Additional CMR Considerations
Hemodynamic Assessment of Outflow Obstruction
Cine CMR can accurately identify the mechanism of
subaortic obstruction in HCM with SAM-septal contact
in both long-axis and basal short-axis images. Subaortic
obstruction will result in high velocity blood flow in the
outflow track area which can often be visualized as a
systolic signal void jet (ie., black) in the region of SAM-
septal contact [69]. In addition, a posteriorly directed
signal void in the left atrium can also be seen and repre-
sents mitral regurgitation directed through the gap
between the anterior and posterior leaflets.
In HCM patients with outflow tract obstruction, phase
velocity flow-mapping sequences can be performed in
order to determine the peak velocity of blood flow
through the outflow tract as well as to quantify the
amount of mitral regurgitation. However, only a small
number of studies have assessed the accuracy of CMR-
derived LV outflow tract velocities compared to contin-
uous-wave Doppler derived pressure gradients [69].
Therefore, it is not certain how well CMR-derived out-
flow tract velocities correspond to velocities obtained by
the standard method of Doppler echocardiography and
assessment with CMR can only be made under resting
(basal) conditions. This represents a limitation for rely-
ing on CMR for gradient assessment as one-third of
HCM patients have outflow obstruction only during
provocation (ie., exercise). However, a recent study
demonstrated that CMR planimetery of the LV outflow
tract diameter could differentiate HCM patients with
rest (or provokable) outflow tract obtstruction from
nonobstructed [69]. Nevertheless, at the current time,
clinical management decisions related to outflow
obstruction should still likely be based on pressure gra-
dients derived from Doppler echocardiography or hemo-
dynamics obtained during coronary catheterization [41].
Surgical septal myectomy
HCM patients with LV outflow obstruction gradient ≥
50 mmHg at rest or with provocation, who have
advanced heart failure refractory to medical therapy, are
candidates for invasive septal reduction therapy to
relieve obstruction and improve limiting symptoms
[3,70]. Surgical myectomy is considered the “gold stan-
dard” for the treatment of outflow obstruction [3]. Con-
temporary surgical strategy requires a thoractomy
followed by an aortotmy providing the surgeon direct
visualization of the LV outflow tract morphology and
the opportunity to resect between 3-12 grams of ventri-
cular septum creating a basal septal trough, which
widens the outflow diameter providing virtually com-
plete elimination of outflow gradients in the vast major-
ity of patients (and a substantially reduction in mitral
regurgitation), resulting in a significant and long-lasting
improvement in heart failure symptoms [71].
CMR has a role in pre-operative surgical myectomy
planning in those HCM patients who are considered
candidates for the operation by characterizing a number
of important morphologic abnormalities related to out-
flow tract anatomy as well as the mitral valve and
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fication of the pattern and distribution of wall thicken-
ing in the basal septum at the point of SAM-septal
contact (particularly when these structures are not well
visualized with echocardiography) can provide the sur-
geon an accurate estimate to the depth of the extended
surgical resection of septal muscle necessary to achieve
optimal relief of outflow obstruction [41].
CMR can identify additional morphologic abnormal-
ities of the mitral valve and papillary muscles, which are
important contributors to the mechanism responsible
for subaortic gradients. Specifically, in those patients
with substantially elongated mitral valve leaflets (Figure
4d) the mitral-septal contact point (and site of subaortic
obstruction) can be displaced distal to its usual position.
As a result, surgical strategy in this case may be altered
to address this situation, by promoting extended muscu-
lar resection as well as the possibility of a combined
approach of septal myectomy and mitral valve repair,
with leaflet extension or plication, in order eliminate
SAM of the mitral valve and absolute reduction of out-
flow gradients [53,72,73].
In addition, a number of other structural abnormalities
of the submitral apparatus notable for proper surgical
myectomy planning can be routinely identified by CMR.
Apically displaced accessory anterolateral (Figure 4e) or a
double bifid papillary muscle act to tether the plane of
the mitral valve toward the ventricular septum facilitating
the drag phenomenon of systolic anterior motion (SAM)
and as a result are associated with a significantly higher
likelihood of having outflow tract obstruction [54,55]. As
a result, the surgeon, as part of an extended septal myect-
omy, often resects these papillary muscles in order to
ensure a pristine hemodynamic result. In addition, anom-
alous insertion of the papillary muscle directly into the
anterior leaflet of the mitral valve in the absence of chor-
dae tendinae will result in mid-systolic apposition of the
papillary muscle and ventricular septum resulting in mid-
cavitary outflow obstruction (Figure 4c) and therefore
often require distal resection of the basal septum as well
as surgical revision of the abnormal papillary muscle [74].
Alcohol septal ablation
Alcohol septal ablation (ASA) is an alternative invasive
septal reduction therapy in which 1-2 cc of alcohol are
injected into an anatomically appropriate septal perfora-
tor artery supplying the basal septum (at the point of
SAM-septal contact) creating a myocardial infarction
resulting (ultimately) in septal thinning, widening of the
LV outflow area and reduction of obstruction [75]. For
HCM patients under consideration for ASA, there are
currently no established CMR-based markers which
identify HCM patients more likely to have an optimal
hemodynamic result with ASA nor in identifying
patients who are at risk for procedural complications
such as complete heart block requiring permanent pace-
maker implantation. CMR can precisely quantify the
amount of tissue necrosis (average of 10% of LV mass)
induced by ASA as well as identifying the relationship
between the location of scarring and outflow tract mor-
phology as well as accurately assessing regression of LV
mass following the procedure [76,77].
LVH and Risk Stratification
LV hypertrophy
Noninvasive imaging of LV wall thickness has proven to
have a role in risk stratification with massive LV hyper-
trophy of ≥ 30 mm demonstrated by 2-D echocardiogra-
phy anywhere in the LV chamber identifies those HCM
patients at highest risk and potentially deserving of ICD
therapy for primary prevention of sudden death
[26,41,78]. Indeed, the presence of massive hypertrophy
alone, in the absence of any additional risk markers,
may be enough to recommend ICD therapy for primary
prevention of sudden death [26]. Therefore, accurate
assessment of maximal wall thickness is an essential
part of the initial evaluation of all HCM patients. Pre-
vious observations have demonstrated that CMR can
identify massive LV wall thickening (≥ 30 mm), confined
to the anterolateral free wall, which was substantially
underestimated in magnitude by 2-dimensional echocar-
diography (Figure 3c and 3d) [42].
LV Mass
Due to the variable distribution of LV hypertrophy in
regions of the LV chamber remote from maximal wall
t h i c k n e s s ,C M R - d e r i v e dL Vm a s sp r o v i d e st h em o s t
accurate assessment of the overall extent of LV hyper-
trophy in this disease. As a result, LV mass may repre-
sent a marker for adverse risk and would therefore seem
to hold promise for aiding in risk stratification [46].
However, long-term prospective CMR studies are
needed before establishing the precise relationship
between LV mass and outcome in this disease.
Significance and Clinical Implications of LGE
Recently, considerable interest has emerged in using
non-invasive in vivo detection of myocardial fibrosis as a
prognostic marker in HCM [26,28,30,32]. Following the
intravenous injection of gadolinium, contrast-enhanced
CMR techniques can be applied to patients with HCM
to detect areas of LGE, which can be planimetered and
the amount quantified and expressed as a % of the total
LV mass. Depending on the selection of patients studied
and which quantification technique used, between 50-
80% of HCM patients have been reported to demon-
strate LGE and when present occupying on average 10%
of the overall LV myocardial volume (Figure 6) [36-39].
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The precise pathophysiologic mechanism responsible for
LGE in HCM currently remains uncertain. Nevertheless,
observations derived from contemporary imaging and
histologic studies provide support for the principle that
LGE may derive from a pathophysiologic cascade in
which repetitive bouts of microvascular ischemia result
from structurally abnormal intramural coronary arteries
(with impaired vasodilatory capacity) responsible, over a
period of time, for myocardial ischemia-mediated myo-
cyte death, ultimately triggering repair in the form of
replacement fibrosis [79].
Indeed, there are a number of avenues of support for
the principle that LGE probably constitutes (or largely
represents) areas of myocardial replacement fibrosis.
Studies in HCM patients with stress-CMR and PET
have demonstrated myocardial blood flow to be substan-
tially reduced in LV segments occupied by LGE and
severely blunted in areas situated adjacent to LGE
[80,81]. In ventricular septal tissue removed from HCM
patients at the time of surgical myectomy, there is a
strong association between the presence (and extent) of
abnormal intramural coronary arteries (by histologic
examination) and LGE (as determined from preoperative
contrast-enhanced CMR studies) [82]. As well, blunted
myocardial blood flow has also been shown to be an
independent predictor of the end-stage phase of HCM
(EF < 50%),[83] a phenotype associated with substan-
tially amounts of myocardial fibrosis[84]. Indeed, the
only reports correlating histologic evidence to CMR
findings of LGE in HCM are a small number of case
reports describing end-stage HCM patients in which
LGE correlates to areas of fibrosis [85,86].
Pattern and distribution of LGE
Virtually any pattern, distribution and location of LGE
c a nb eo b s e r v e di nH C M ,a l t h o u g hL G En e v e rc o r r e -
sponds to a coronary vascular distribution (Figure 6)
[37,87,88]. LGE is most commonly located in both ven-
tricular septum and free wall (over 30% of patients), but
less commonly can be confined to the free wall, septum,
apex, and the areas of right ventricular insertion into
ventricular septum [37]. In addition, LGE can also occur
Figure 6 Contrast-enhanced CMR images in 6 different HCM patients demonstrating the diverse pattern and extent of late
gadolinium enhancement in this disease. (A) extensive transmural LGE in the anterior wall (small arrows) with smaller focal area in the
inferior wall (small arrows); (B) mid-myocardial LGE in the lateral wall (small arrows) and diffuse LGE in the ventricular septum which extends into
the RV wall (large arrows) in a 26 year-old man with “end-stage” phase of HCM with an ejection fraction of 40%; (C) LGE confined to the LV
apex (arrows); (D) LGE localized to the insertion area of the RV wall into the anterior (large arrow) and posterior ventricular septum (small arrow);
(E) transmural LGE involving the majority of the ventricular septum (large arrow) and lateral wall (small arrow). (F) Basal short-axis image with
transmural LGE located predominantly in the ventricular septum (arrows). RA = right atrium; RV = right ventricle; LA = left atrium; LV = left
ventricle
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[47,48] and isolated to the papillary muscles [54], sug-
gesting that a similar process of myocardial fibrosis
which occurs in the LV can also occur (although much
less frequently) in other areas of the heart.
Transmural extent of LGE in not uncommon, occur-
ring in one-half of HCM patients [37]. A significant but
modest relationship is present between hypertrophy and
LGE. Patients with LGE have greater maximal LV wall
thickness and LV mass index than patients without LGE
[37,87,88]. On an individual patient basis, a relationship
is also present between segmental LV wall thickness and
LGE [37,88].
Adverse LV remodeling
One of the strongest and most consistent observations
derived from a number of contemporary cross-sectional
studies is the inverse relationship between ejection frac-
tion and LGE in HCM. LGE extent is greatest in HCM
patients with EF < 50%. (ie., end-stage phase) while
those with hyperdynamic LV systolic function have
comparatively minimal LGE [37,87,88]. However, HCM
patients with low-normal EF (50-65%) show amounts of
LGE that overlap those in the end-stage phase, and also
demonstrate LV cavity dimensions that are more similar
to the end-stage than patients with intact systolic func-
tion [89]. These observations would suggest some HCM
patients with low-normal LV function are at risk of pro-
gressive fibrosis transitioning to a phase of more
advanced LV remodeling associated with systolic dys-
function. However, due to the relatively recent introduc-
tion of CMR into cardiology practice, longitudinal
follow-up studies characterizing the development and
natural history of LGE in HCM are not yet available.
Consequently, it is not possible at this time to deter-
mine if a threshold amount of LGE exists which identi-
fies HCM patients at future risk of progressive
remodelling. Nevertheless, these observations have
potentially important clinical implications as HCM
patients with systolic dysfunction represent a high risk
subgroup at increased risk of sudden death and
advanced heart failure symptoms prompting considera-
tion for ICD therapy and alternative medical therapy e.
g., ACE-inhibitors or aldosterone inhibitors to improve
adverse LV remodelling [84]. Therefore, HCM patients
identified with low-normal LV ejection fraction should
undergo close clinical follow-up with serial imaging for
prospective detection of changes in symptoms and LV
structure.
Heart failure symptoms with preserved EF
At present, the precise impact of LGE on the develop-
ment of heart failure symptoms is unresolved. A few
studies have reported a weak but significant relationship
between LGE and progressive heart failure symptoms/
death in HCM (and the risk proportional to the extent
of LGE) [37,38]. However, in one such study, the clinical
relevance of this relationship was driven predominantly
by unplanned hospitalizations, a “soft” clinical end-point
in HCM [38]. In addition, at this time it is not estab-
lished that LGE provides additional information with
respect to future risk of heart failure symptoms beyond
the currently established predictors of symptom progres-
sion in this disease such as LV outflow tract obstruction
[90].
Sudden Death
Despite considerable advances, risk stratification in
HCM remains incomplete as some at-risk patients are
not identified by the conventional risk factors suggesting
a need to identify novel markers of susceptibility to sud-
den death risk [12,26,91,92]. Therefore, in this regard,
there is substantial interest in exploring other modalities
such as contrast-enhanced CMR. Indeed, based on
recent cross-sectional studies, a strong association has
been demonstrated between LGE and ventricular
tachyarrhythmias on ambulatory 24-hour Holter ECG
(Figure 7) [39,93-97]. Up to a 7-fold increased risk for
p o t e n t i a ll e t h a lv e n t r i c u l ar tachyarrythmias has been
demonstrated among HCM patients with LGE com-
pared to those without LGE [93]. These observations
would suggest that LGE may represent an unstable
arrythmogenic substrate responsible for ventricular
tachyarrythmias in HCM.
Since nonsustained ventricular tachycardia is an inde-
pendent risk factor for sudden death in this disease [98],
the relationship between ambulatory ventricular tachyar-
rhythmia and LGE support the possibility that contrast-
enhanced CMR could represent a novel risk marker and
thereby improve current risk stratification strategies by
identifying HCM patients at increased risk of sudden
death. In this regard, 4 prospective (short-term) out-
come studies with relatively small number of HCM
patients have been published that have demonstrated
conflicting results regarding the relation between LGE
and sudden death and/or appropriate therapy for ventri-
cular tachycardia/fibrillation (table 1) [36-39]. When
data from these studies were combined, LGE was more
common in patients who experienced sudden death or
an appropriate ICD discharge than those who did not
resulting in a significant but weak relationship between
the presence of LGE and risk for sudden death (table 1).
Therefore, available data do not strongly support LGE
as a primary independent risk factor for sudden death in
HCM [26]. As a result, recommendations for primary
prevention ICDs should not be based solely on the pre-
sence of LGE in individual patients. Nevertheless, given
the strong association of LGE and ambulatory ventricu-
lar arrhythmias, it is not unreasonable to give some
weight to this finding as an arbitrator in reaching
recommendations for prophylactic ICDs in selected
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(Figure 8) [93].
The clinical significance of LGE is currently one of the
most important and debated clinical questions in HCM
[28,99]. Resolving this issue will require demonstrating
that LGE is a clinically relevant marker of sudden death
in large, prospectively selected cohorts with substantial
number of patients followed over periods of time suffi-
cient to ultimately provide the statistical robustness to
establish the independent contribution of LGE to sud-
den death (in what is essentially a low-risk disease
overall). In addition, it is imperative that future studies
comparing LGE to outcome only employ established
well-defined end-points clinically relevant to HCM, as
well as compare the predictive value of LGE to the 5
established noninvasive risk markers currently used to
identify patients at-risk.
Another point in establishing clinical relevance for
contrast-enhanced CMR is the relationship of presence
vs. extent of LGE with respect to outcome. The majority
of follow-up contrast-enhanced CMR studies have
reported only an association between the presence of
Figure 7 Prevalence of arrhythmia on 24-hour Holter ECG with respect to presence of late gadolinium enhancement in patients with
HCM. Adapted with permission, from Adabag et al.[93]. ECG = electrocardiogram; HCM = hypertrophic cardiomyopathy; LGE = late
gadolinium enhancement; NSVT = nonsustained ventricular tachycardia; PVC = premature ventricular contraction; SVT = supraventricular
tachychardia
Table 1 Comparison of 4 short-term follow-up contrast-enhanced CMR studies in HCM
Study No. Patients LGE Quantification
Technique
Total SD Events LGE Positive with SD LGE Negative with SD p-value
Bruder et al 2010 220 ≥ 2S D
Threshold
11 10 1 0.1
O’Hanlon et al 2010 217 FWHM 4 3 1 1.0
Rubinshtein et al 2010 424 Visual 8 8 0 0.002
Maron et al 2008 202 ≥ 6 SD Threshold 7 4 3 0.05
Overall 1063 ———————————— 30 25 5 0.04
Abbreviations: FWHM = full width half maximum; LGE = late gadolinium enhancement; No. = number; SD = standard deviation
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reported prevalence of LGE is over 50% (up to 80% in
one study)[97]. Therefore, even if some relationship can
be derived between the presence of LGE and sudden
death, LGE alone would not qualify as a practical risk
marker as simply too many HCM patients would be
identified for primary prevention ICDs. Therefore, for
contrast-enhanced CMR to be a clinically useful tool for
management decisions, it will likely be necessary to ulti-
mately demonstrate that risk of adverse outcome is
related to extent of LGE or when LGE is combined with
the other currently established prognostic markers into
a composite risk score for sudden death.
LGE Disclaimers in HCM
Does LGE always represent myocardial fibrosis in HCM?
Over the last several years, it has become increasingly
common in the HCM literature and clinical arena to
equate areas of LGE directly to myocardial fibrosis
[28,82,85-88,93,95,100]. This assumption is largely based
on extrapolation from CMR-based animal models of myo-
cardial fibrosis in which areas of fibrosis from the core
infarct correlate to areas of LGE[101], as well as the asso-
ciation in HCM patients between areas of abnormal myo-
cardial blood flow and hyperenhancement [79,81,102]. Yet
in HCM, a number of obstacles continue to make it diffi-
cult to understand the precise histologic basis of LGE in
this disease, including lack of a suitable HCM animal
model and difficulty in obtaining post-mortem and
explanted hearts for histopathologic examination close to
the time of a prior clinical CMR examination. Indeed, the
only correlative studies which directly relate CMR and his-
topathologic findings are derived from explanted end-stage
HCM hearts [85,86], making it difficult to extrapolate
those findings to more typical HCM patients with normal
preserved EF. However, these studies do show extensive
amounts of fibrosis responsible for the adverse LV remo-
delling in this subgroup of HCM patients [85,86].
Figure 8 Role of CMR in Sudden Death Risk Stratification. Results of contrast-enhanced CMR with late gadolinium enhancement could be
used as a potential arbitrator to arrive at a decision regarding ICD therapy for primary prevention of sudden death in HCM patients in whom
risk still remains ambiguous after assessment with current conventional risk factors.
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would suggest that, in fact, not all LGE may represent
myocardial fibrosis in this disease. First, LGE in HCM is
more commonly found in those LV segments which are
the thickest with normal regional systolic function
[37,87-89]. This observation is in direct opposition to
that in patients with ischemic heart disease, in which
LV segments with LGE are often thinned with asso-
ciated wall motion abnormalities [103]. Second, exten-
sive amounts of LGE can be present in asymptomatic
HCM patients who have achieved advanced age (> 60
years) with normal systolic function and without adverse
disease consequences such as potentially lethal arrhyth-
mias, heart failure symptoms or adverse LV remodelling
[37]. Furthermore, among end-stage HCM patients the
amount of LGE often exceeds that observed in any
other cardiovascular disease, including patients who
have suffered large ST-segment elevation myocardial
infarction suggesting that even within this subgroup of
patients not all LGE maybe myocardial scar [84,89].
Therefore, based upon the totality of these observa-
tions it would be reasonable to consider that some LGE
in HCM may represent histopathology which is not a
result of myocardial scarring from replacement fibrosis.
For instance, gadolinium may deposit within the diffuse
interstitial collagen (matrix) compartment between nor-
mally aligned myofibrils or areas of perivascular fibrosis.
Matrix collagen constitutes a greatly expanded extracel-
lular tissue volume partially responsible for increased
LV wall thickness, represents a primary morphologic
feature of HCM, and provides an opportunity for gadoli-
nium accumulation that may not reflect true replace-
ment fibrosis. In addition, disorganized myocyte
architecture will result in expanded areas of myocardial
matrix where gadolinium could aggregate. Consistent
with this point is the fact that one of the most common
locations of focal LGE in HCM is at the insertion of RV
wall into anterior or posterior ventricular septum
[37,39,87,88]. Kuribayashi et al.[104] has shown in post-
mortem HCM hearts that this particular area of the LV
chamber is characterized histologically by an expanded
extracellular space created by the arrangement of inter-
secting myocardial fibers (at the juncture points of both
the LV and RV) and therefore accumulation of gadoli-
nium in this area is unlikely to represent replacement
fibrosis.
With current CMR technology it is not possible to
reliably distinguish interstitial (matrix) from replacement
fibrosis, or an expanded matrix compartment created by
myocyte disarray [100]. This may be an important lim-
itation to contrast-CMR, as these forms of histopathol-
o g yi nH C Mm a yp o r t e n dd i f f e r e n tc l i n i c a l
consequences, particularly regarding susceptibility to
potentially life-threatening arrhythmias.
Nevertheless, there has been interest in using CMR to
differentiate myocardial substrates of different histologic
composition. This principle has been addressed predo-
minantly in patients with atherosclerotic coronary artery
disease and prior myocardial infarction, in which areas
of intermediate LGE signal intensity (ie., “grey-zone”)
correlate histologically to regions of ‘tissue heterogene-
ity’ (mixture of isolated myocytes and fibrosis), while
regions of higher signal intensity LGE correlate with
core infarct zones comprised of only replacement scar
[105]. Identification of areas of tissue heterogeneity are
of potential importance, as these regions may represent
am o r ea r r t h y m o g e n i cs u b s t r a t et h a nt h ec o r ei n f a r c t
[106].
In HCM, areas of lesser signal intensity LGE are also
common but have largely been ignored in prior analysis
of hyperenhancement in this disease and therefore their
potential for generating life-threatening ventricular
arrhythmias largely ignored [37-39,89,93]. However, a
recent investigation in HCM, applying a similar imaging
strategy to that used in ischemic cardiomyopathy to
identify the “grey zone” border surrounding core infarct,
demonstrated that magnitude of intermediate LGE sig-
nal intensity (≥ 4 but < 6 SD above the mean SI of
nulled myocardium) was a more reliable LGE discrimi-
nator for identifying HCM patients with ambulatory
complex arrhythmias such as NSVT than high signal
intensity LGE (≥ 6 SD) [107]. These data underscore the
potential value in assessing regions of intermediate sig-
nal intensity LGE, which may identify another abnormal
myocardial substrate more prone to ventricular tachyar-
rhythmias. In order to resolve this issue, further longitu-
dinal studies are necessary to assess whether the
character of LGE (intermediate vs. higher signal inten-
sity) is a predictor of clinical outcome in HCM patients
with preserved systolic function.
Quantification of LGE in HCM
Over the last several years, numerous techniques have
been proposed to assess extent of LGE in HCM reflect-
ing the uncertainty which persists regarding the most
appropriate strategy for assessing hyperenhancement in
this disease [108-112]. The most widely used techniques
have been a variety of semi-automated algorithms which
identify high signal intensity LGE pixels after applying a
grayscale threshold a number of standard deviations
(SD) above the mean signal intensity within a remote
region of interest (ROI) containing normal “nulled”
myocardium (i.e. 2, 4, 5 or 6 [SD])(Figure 9a) or peak
intensity of scarred myocardium (i.e. full width at half
maximum [FWHM]). In addition, the Raleigh curve
method is a novel quantitative technique which
addresses limitations inherent in defining a ROI (ie., the
assumption that within an ROI the signal intensity pix-
els always conform to a Gaussian distribution) by
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erate a more ideal myocardial signal intensity distribu-
tion curve [108].
These thresholding algorithms has been most exten-
sively studied in patients with ischemic cardiomyopathy,
where grayscale techniques using 2 SD above the mean
of normal myocardial SI or FWHM have been shown to
correlate well with the spatial extent of the infarct
[101,113]. In addition, because the infarct scar is sur-
rounded by an otherwise structurally normal myocar-
dium there are no significant differences in the amount
of LGE if a 2SD threshold is applied compared to using
other grayscale thresholds.
However, HCM represents a distinctly different dis-
ease entity in which abnormal myocardial substrate
(interstitial-matrix, replacement fibrosis and areas of
myocyte disarray) involve large proportions of LV
myocardium [106,114-116]. Therefore, directly extrapo-
lating fundamental principles of LGE analysis from
patients following CAD-related myocardial infarction to
those with HCM may incorporate flawed assumptions
[111]. For example, in an individual HCM patient there
may be significant differences in amount of LGE identi-
fied depending on which greyscale threshold technique
is chosen, with a 2SD threshold resulting in a 2-fold
greater amount of hyperenhancement compared to a
6SD threshold (Figure 9B) [108,111,112]. However, 6 SD
and FWHM have been found to most closely approxi-
mate the extent of fibrosis compared with visual assess-
ment (or the Raleigh curve method) and to be the most
reproducible method for quantification of LGE in HCM
compared to other grayscale thresholds (Figure 9b)
[108,111,112]. Therefore, in the absence of data compar-




Figure 9 Quantification of LGE.( A) Identical LV short-axis contrast-enhanced cardiovascular MR images show LGE depicted with gray-scale
thresholding techniques at 2, 4, and 6 SDs above mean signal intensity of normal remote myocardium, with visual assessment, and with 2 SDs
above mean of external region of interest (ROI). LV endocardium and epicardium are outlined in red and green, respectively. Solid black areas in
LV myocardium represent areas of delayed enhancement at corresponding semiautomated threshold; (B) Graph illustrates volumes of delayed
enhancement (horizontal axis values) assessed by using various gray-scale thresholding techniques (2, 4, and 6 SDs above mean), visual
assessment, and an external region of interest. Reproduced with permission, from Harrigan C et al.[113]
Maron Journal of Cardiovascular Magnetic Resonance 2012, 14:13
http://www.jcmr-online.com/content/14/1/13
Page 16 of 21HCM patient with preserved EF (or appropriate animal
models), it seems most reasonable at this time to pro-
mote the use of either of these two methods for quanti-
fying LGE in HCM.
Furthermore, there are a number of technical issues to
consider as potential limitations with respect to LGE
images. The quality of contrast-enhanced images can be
affected by the selection of poor inversion times and
motion artifact, making it difficult to reliably determine
in such cases whether LGE represents abnormal histo-
pathology versus “background noise” [117]. In addition,
a number of different types of sequences are now being
used to acquire LGE images, including 3-D segmented
inversion-recovery, phase-sensitive inversion-recovery
and equilibrium contrast CMR [117-119]. There are cur-
rently no data available which compare the extent of
LGE identified using these different techniques, and
there is variability among individual operators with
respect to optimizing respective image parameters. The
limitations with respect to quantification of LGE in
HCM is underscored by the fact that the 4 short-term
follow-up contrast-enhanced CMR studies in this dis-
ease have each applied a different quantification method
to determine the presence and/or extent of LGE, which
provides an additional explanation for why the results of
these outcome studies are so dissimilar [36-39].
At present, the totality of these data suggests a note of
caution is appropriate in interpreting the significance of
LGE from a histologic perspective in patients with
HCM. It is reasonable to conclude that in end-stage
HCM patients the majority of LGE represents myocar-
dial replacement fibrosis responsible for the adverse LV
remodeling evident. It remains less clear to what extent
LGE equates to scar formation among the more typical
HCM patients with preserved EF, who comprise the vast
majority of patients with this disease. Nevertheless, even
if all hyperenhancement does not equate with fibrosis,
LGE may still prove to be an important clinical marker
for prognosis in this disease. In addition, at this early
juncture, there still remains a great need for standardi-
zation of LGE quantification methods and sequence
acquisition, given that the substantial amount of varia-
bility evident among these techniques represents a
potential limitation in applying CMR to routine clinical
decision-making.
Conclusions
Over the last decade, the unique imaging strengths of
CMR have led to improved diagnostic capabilities and
expanded our understanding and appreciation of the
diverse phenotypic expression of this complex genetic
heart disease. In addition, CMR has an emerging role in
the assessment of risk in patients with HCM, as sub-
stantially increased LV mass and late gadolinium
enhancement have been associated with increased likeli-
hood of future adverse cardiovascular events. Taken
together, these observations underscore an important
and growing role for CMR in the contemporary evalua-
tion of HCM patients and support the need for future
longitudinal studies to clarify whether CMR-derived
variables will be independent predictors of sudden death
and disease progression.
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